Import Your Data

FAQ

More QuickView FAQs

QuickView

0
Meta-
Analysis

Bookmark Forward

QuickView for Cevimeline (compound)

Summary
General Info

PubChem

PubChem Compound 11041760

PubChem Compound 11041760

Name:	cevimeline
PubChem Compound ID:	11041760
Molecular formula:	C₁₀H₁₇NOS
Molecular weight:	199.314 g/mol

DrugBank

Identification

Name:	cevimeline
Name (isomeric):	DB00185
Drug Type:	small molecule
Synonyms:	Cevimeline hydrochloride hydrate; Cevimeline hydrochloride hemihydrate; Cevimeline hydrochloride
Brand:	Evoxac, Saligren
Category:	Parasympathomimetics, Muscarinic Agonists
CAS number:	107233-08-9

Pharmacology

Indication:	For the treatment of symptoms of dry mouth in patients with Sjögren's Syndrome.
Pharmacology:	Cevimeline is a cholinergic agonist which binds to muscarinic receptors. Muscarinic agonists in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands and increase tone of the smooth muscle in the gastrointestinal and urinary tracts.
Mechanism of Action:	Muscarinic agonists such as cevimeline bind and activate the muscarinic M1 and M3 receptors. The M1 receptors are common in secretory glands (exocrine glands such as salivary and sweat glands), and their activation results in an increase in secretion from the secretory glands. The M3 receptors are found on smooth muscles and in many glands which he... show more » Muscarinic agonists such as cevimeline bind and activate the muscarinic M1 and M3 receptors. The M1 receptors are common in secretory glands (exocrine glands such as salivary and sweat glands), and their activation results in an increase in secretion from the secretory glands. The M3 receptors are found on smooth muscles and in many glands which help to stimulate secretion in salivary glands, and their activation generally results in smooth muscle contraction and increased glandular secretions. Therefore, as saliva excretion is increased, the symptoms of dry mouth are relieved. show less «
Absorption:	Rapidly absorbed with peak concentration after 1.5 to 2 hours
Protein binding:	< 20%
Biotransformation:	Primarily hepatic, isozymes CYP2D6 and CYP3A4 are responsible for the metabolism of cevimeline. Approximately 44.5% of the drug is converted to cis and trans-sulfoxide, 22.3% to glucuronic acid conjugate, and 4% to N-oxide of cevimeline. Approximately 8% of the trans-sulfoxide metabolite is then converted into the corresponding glucuronic acid conjugate.
Route of elimination:	After 24 hours, 84% of a 30 mg dose of cevimeline was excreted in urine.
Half Life:	5 ± 1 hours
Affected organisms:	Humans and other mammals

Interactions

Drug interaction:

Conivaptan	Conivaptan may increase the serum concentration of CYP3A4 substrates such as cevimeline. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates.
Tacrine	The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Cevimeline, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity.

Targets

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M1

Enzymes

Cytochrome P450 2D6

Cytochrome P450 3A4

Dimethylaniline monooxygenase [N-oxide-forming] 1